Immundnz was founded by Dr. Masih Alam and Dr. Robert-Jan Lamers. The company is based in Alderley Park, Cheshire, UK.
Immundnz offers specialised support in immunology and in vitro research. We provide a range of standard and custom-made assays to biopharmaceutical researchers and professionals worldwide. Due to our experience and track record, you can rely on us as your solid partner in immunology and in vitro projects.
Immundnz has an entrepreneurial team of highly-skilled and qualified experts in immunology, biochemistry and analytical chemistry.
Dr. Masih Alam
Director and Founder
Dr. Masih Alam is founder of Immundnz. He has worked for over 15 years in both academic and business settings. In 2012, he founded ImmunoSYS, a company that proposes immunological solutions to the biopharmaceuticals market. ImmunoSYS has developed long term industrial projects with biotech companies in Europe and South Asia. Earlier in his career, Dr. Alam worked as a divisional director at the Alliance Francaise de Dhaka. He earned his PhD in immunology from the University of Manchester.
Dr. Ir. Robert-Jan Lamers
Director and Founder
Dr. Ir. Robert-Jan Lamers is founder of Immundnz. He has over 15 years of experience in the biopharma and CRO industry and research organisations. He founded the company Abundnz in 2011, which he developed into a solid analytical partner for biotech and pharma industries worldwide. He is member of the Advisory Board and Supervisory Committee of Utrecht University of Applied Sciences. Dr. Lamers is analytical chemist by training and holds a PhD from the University of Leiden.
Immundnz is supported by an advisory board with seasoned professionals in tissue modelling, immunology, preclinical research and drug toxicology, analytical chemistry, mathematical modelling, business and capital development and entrepreneurship.
Dr. Philip Hedge
Philip Hedge (PhD) is a bioscientist with 6 years of academic research, 24 years of experience of cancer drug discovery at AstraZeneca (AZ) and 4 years as an independent consultant to Biotech. Philip has conducted and led research across all phases of research, including new target discovery, lead generation, lead optimisation and preclinical support for compounds in clinical development. In his 10 years as Director of Cancer Bioscience he led a group of more than 200 bioscientists in delivering the preclinical and translational science in support of the AZ Oncology portfolio. As a project leader he has led many cross functional drug discovery projects, and many collaborations with academia or Biotech. His strategic vision and drive brought many new technological and scientific innovations into the AZ organisation. He also led cross therapeutic area bioscientist development and science/technology sharing. He offers clear insight into the critical studies required to effectively evaluate target relevance in disease, identify clinical candidates and position experimental therapeutics appropriately in the clinic.
Prof. Neville Ford
Professor Neville Ford took his MA (Oxon) in 1983, an MSc (from Manchester in 1986) and a PhD in 1991 from Liverpool. He was invited to become a Fellow of the Institute of Mathematics and its Applications for services to Mathematics. He is a Fellow of the Higher Education Academy and is the founder and director of the University of Chester Mathematical Sciences Research Group. He supervises PhD students and conducts his own research, in collaboration with members of the Chester group and with researchers elsewhere in Europe. His research interests combine theory, computational simulations and modelling applications of functional differential equations in materials science, in the environmental sciences, in the biosciences, and in medicine. He has experience in mathematical analysis of immunologic cell
Prof. Julie Gough
Professor Julie Gough is a cell biologist whose research interests are in tissue engineering of mechanically sensitive connective tissues such as bone, cartilage, skeletal muscle and the intervertebral disc. Her research includes controlling cell responses at the cell-biomaterial interface by engineering defined surfaces. This includes analysis and control of cells such as osteoblasts, chondrocytes, fibroblasts, keratinocytes, myoblasts and macrophages on a variety of materials and scaffolds. Her research also involves development of scaffolds for tissue repair such as novel hydrogels and various porous and fibrous materials.
She has published over 70 papers and collaborates widely within academia and industries such as Johnson and Johnson and Smith and Nephew.
Dr. Lloyd Pane
Lloyd Pane (PhD) is Executive Vice President Anti-infective Operations at Evotec. Prior to co-founding Euprotec, now Evotec, he spent nearly 20 years in the biopharmaceutical and CRO sectors where he directed a number of drug discovery programmes in the infectious disease, oncology and inflammation therapeutic areas.
Jobs and Placement
We are always interested to meet talented people. We also offer student placement internships. If you are interested to join our company, please contact us.